Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc....
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
NEW YORK , Nov. 27, 2025 /PRNewswire/ -- We wish you a Happy Thanksgiving and Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"),...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that following the announcement on November 14, 2025 of the entering...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
MILWAUKEE , Nov. 14, 2025 /PRNewswire/ -- The Ademi Firm is investigating Repare (Nasdaq: RPTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...
- Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 2026 - ...